[{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Evofem Biosciences Secures up to $25 Million in Convertible Note Financing","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Financing","leadProduct":"L-Lactic Acid","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0.029999999999999999,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"Intravaginal Gel","sponsorNew":"Evofem Biosciences \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evofem Biosciences Announces Three New Phexxi\u2122 or Presentation at 2020 ACOG","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves Evofem Biosciences' Phexxi\u2122 (Lactic acid, Citric acid and Potassium bitartrate), the First and Only Non-Hormonal Prescription Gel for the Prevention of Pregnancy","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evofem Biosciences Announces Pivotal Phase 3 AMPOWER Study Results For Phexxi\u2122 in Contraception","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evofem Biosciences Announces U.S. Commercial Launch of Phexxi\u2122, the First and Only Non-Hormonal, Prescription Contraceptive Vaginal Gel","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evofem Biosciences Announces Presentations on Phexxi and EVO100 at Key Medical Society Meetings","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Evofem Biosciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravaginal Gel","sponsorNew":"Evofem Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Adjuvant Capital","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Evofem Biosciences Secures $25 Million Strategic Investment from Adjuvant Capital","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Financing","leadProduct":"L-Lactic Acid","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Evofem Biosciences","amount2":0.029999999999999999,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"Intravaginal Gel","sponsorNew":"Evofem Biosciences \/ Adjuvant Capital","highestDevelopmentStatusID":"10","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evofem Biosciences Announces First Patient Enrolled in Pivotal Phase 3 Trial of EVO100 for Prevention of Chlamydia and Gonorrhea","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Evofem Biosciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravaginal Gel","sponsorNew":"Evofem Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evofem Biosciences Provides Update on Pivotal Phase 3 Trial of EVO100 for Prevention of Chlamydia and Gonorrhea","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Evofem Biosciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravaginal gel","sponsorNew":"Evofem Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Evofem Biosciences Announces Pricing of $30 Million Public Offering of Common Stock","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Public Offering","leadProduct":"L-Lactic Acid","moa":"Vaginal pH","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0.029999999999999999,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Morgan Stanley","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evofem Biosciences to Deliver Keynote Address and Present Two Phexxi Data Sets at NCODA 2021 National Spring Forum","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"Vaginal pH","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Vaginal gel","sponsorNew":"Evofem Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evofem Biosciences Receives Fast Track Designation for EVO100 for Prevention of Gonorrhea in Women","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"pH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Evofem Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"H.C. Wainwright","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Evofem Biosciences Announces Closing of $50 Million Public Offering","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Public Offering","leadProduct":"L-Lactic Acid","moa":"Vaginal pH","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0.050000000000000003,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0.050000000000000003,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ H.C. Wainwright","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data on EVO100 for the Prevention of Chlamydia and Gonorrhea in Women to be Presented at ISPOR 2021","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"pH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Evofem Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Keystone Capital Partners","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Evofem Biosciences Announces $10 Million Registered Direct Offering of Series B Preferred Stock","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Series B Financing","leadProduct":"L-Lactic Acid","moa":"Vaginal pH","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0.01,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Keystone Capital Partners","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galderma Receives FDA Approval for New SCULPTRA\u00ae Label, Offering More Options to Aesthetic Partners","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"Collagen hydrolysis","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Galderma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Galderma \/.."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Journal of Sexual Medicine Publishes Sexual Satisfaction Data Involving Phexxi\u00ae from Evofem's Phase 3 AMPOWER Clinical Trial","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"Vaginal pH","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evofem Presents Data Detailing Fewer Urinary Tract Infections in Women Using Phexxi in the Phase 3 AMPOWER Clinical Trial","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"Vaginal pH","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Bora Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evofem Biosciences to Decrease Cost of Goods 45 Percent Through New Partnership with Bora Pharmaceutical Services for the Commercial Manufacturing of Phexxi\u00ae","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Partnership","leadProduct":"L-Lactic Acid","moa":"Vaginal pH","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Gel","sponsorNew":"Evofem Biosciences \/ Bora Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Piper Sandler & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evofem Biosciences Announces Proposed Public Offering","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Public Offering","leadProduct":"L-Lactic Acid","moa":"Vaginal pH","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Gel","sponsorNew":"Evofem Biosciences \/ Piper Sandler & Co","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phexxi\u00ae Prevented 99% of Pregnancies Per Act of Intercourse in a Post Hoc Analysis of Phase 3 AMPOWER Clinical Trial Data","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"Vaginal pH","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Gel","sponsorNew":"Evofem Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Piper Sandler & Co.","pharmaFlowCategory":"D","amount":"$26.6 million","upfrontCash":"Undisclosed","newsHeadline":"Evofem Biosciences Announces Pricing of Approximately $26.6 Million Public Offering","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Public Offering","leadProduct":"L-Lactic Acid","moa":"Vaginal pH","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0.029999999999999999,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"Gel","sponsorNew":"Evofem Biosciences \/ Piper Sandler & Co.","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phexxi\u00ae Mechanism of Action Article Published in the Journal of Therapeutic Advances in Reproductive Health","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"Vaginal pH","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Gel","sponsorNew":"Evofem Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evofem Announces Completion of Last Subject Last Visit (LSLV) in Registrational Phase 3 \"EVOGUARD\" Trial Evaluating Phexxi\u00ae for the Prevention of Chlamydia and Gonorrhea in Women","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"Vaginal pH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Gel","sponsorNew":"Evofem Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Large Commercial Payer Adds Phexxi\u00ae to Formulary for Standard Plans Nationwide","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"Vaginal pH","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Gel","sponsorNew":"Evofem Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evofem Announces Issuance of U.S. Patent Covering Phexxi\u00ae Composition of Matter","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"Vaginal pH","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Gel","sponsorNew":"Evofem Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evofem Biosciences Announces Approval of Phexxi in Nigeria","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"Vaginal pH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Gel","sponsorNew":"Evofem Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AMWC 2023: Data From Sculptra\u00ae Cheek Wrinkle and Alluzience\u00ae Star Studies Reinforce Strength of Galderma\u2019s Broad Aesthetic Portfolio","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Galderma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Galderma \/.."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Aditxt","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aditxt, Inc. Enters into Definitive Agreement to Acquire Evofem Biosciences, Inc., Creator of Phexxi\u00ae, the First and Only FDA-Approved Hormone-Free Contraceptive Gel, to Address Diverse Reproductive Health Needs of Women Globally","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Acquisition","leadProduct":"L-Lactic Acid","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Gel","sponsorNew":"Evofem Biosciences \/ Aditxt","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Bio.."}]
Find Clinical Drug Pipeline Developments & Deals for L Lactic Acid API
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Market Place
Reset All
